{"organizations": [], "uuid": "3af09f0c50ecb4b4e94c56db4a36994060adfc9b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-achaogen-announces-fda-acceptance/brief-achaogen-announces-fda-acceptance-of-new-drug-application-with-priority-review-for-plazomicin-idUSASB0BZFE", "country": "US", "domain_rank": 408, "title": "BRIEF-Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T15:11:00.000+02:00", "replies_count": 0, "uuid": "3af09f0c50ecb4b4e94c56db4a36994060adfc9b"}, "author": "", "url": "https://www.reuters.com/article/brief-achaogen-announces-fda-acceptance/brief-achaogen-announces-fda-acceptance-of-new-drug-application-with-priority-review-for-plazomicin-idUSASB0BZFE", "ord_in_thread": 0, "title": "BRIEF-Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin", "locations": [], "entities": {"persons": [], "locations": [{"name": "european union", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "brief-achaogen announces fda", "sentiment": "negative"}, {"name": "achaogen inc", "sentiment": "none"}, {"name": "priority review for plazomicin reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 12 PM / Updated 10 minutes ago BRIEF-Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin Reuters Staff 1 Min Read \nJan 2 (Reuters) - Achaogen Inc: \n* ACHAOGEN ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR PLAZOMICIN FOR TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND BLOODSTREAM INFECTIONS \n* ACHAOGEN - INTENDS TO SUBMIT APPLICATION FOR MARKETING AUTHORIZATION FOR PLAZOMICIN IN EUROPEAN UNION IN 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-02T15:11:00.000+02:00", "crawled": "2018-01-02T15:28:29.030+02:00", "highlightTitle": ""}